137 related articles for article (PubMed ID: 37772428)
21. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099
[TBL] [Abstract][Full Text] [Related]
22. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
23. Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multicentre, retrospective cohort study.
Schmidt M; Hajage D; Landoll M; Pequignot B; Langouet E; Amalric M; Mekontso-Dessap A; Chiscano-Camon L; Surman K; Finnerty D; Santa-Teresa P; Arcadipane A; Millán P; Roncon-Albuquerque R; Blandino-Ortiz A; Blanco-Schweizer P; Ricart P; Gimeno-Costa R; Albacete CL; Fortuna P; Schellongowski P; Dauwe D; Winiszewski H; Kimmoun A; Levy B; Hermans G; Grasselli G; Lebreton G; Guervilly C; Martucci G; Karagiannidis C; Riera J; Combes A;
Lancet Respir Med; 2023 Feb; 11(2):163-175. PubMed ID: 36640786
[TBL] [Abstract][Full Text] [Related]
24. Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia.
Puła B; Pruszczyk K; Pietrusza E; Morawska M; Piszczek W; Kalicińska E; Szeremet A; Tryc-Szponder J; Wąsik-Szczepanek E; Drozd-Sokołowska J; Krzemień H; Rejus A; Gajewska M; Wiśniewski K; Wysocki M; Majeranowski A; Paszkiewicz-Kozik E; Steckiewicz P; Szukalski Ł; Bołkun Ł; Długosz-Danecka M; Giannopoulos K; Jamroziak K; Lech-Marańda E; Hus I
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158826
[TBL] [Abstract][Full Text] [Related]
25. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
26. COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study.
Kochneva ОL; Kislova M; Zhelnova EI; Petrenko AA; Baryakh EA; Yatskov KV; Dmitrieva EA; Misurina EN; Nikitin KE; Vasilieva EJ; Samsonova IV; Ptushkin VV; Baranova A; Nikitin EA
Leuk Lymphoma; 2022 Jul; 63(7):1607-1616. PubMed ID: 35156528
[TBL] [Abstract][Full Text] [Related]
27. EXPRESSION OF IMMUNOGLOBULIN SEQUENCES HOMOLOGOUS TO ANTI-SARS-CoV-2 ANTIBODIES AND HIV IN CHRONIC LYMPHOCYTIC LEUKEMIA CASES.
Abramenko I; Bilous N; Chumak A; Martina Z; Dyagil I; Bazyka D
Exp Oncol; 2022 Nov; 44(3):208-212. PubMed ID: 36325706
[TBL] [Abstract][Full Text] [Related]
28. Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with chronic lymphocytic leukaemia.
Barber VS; Peckham N; Duley L; Francis A; Abhishek A; Moss P; Cook JA; Parry HM
BMJ Open; 2023 Sep; 13(9):e077946. PubMed ID: 37770269
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.
Molica S; Giannarelli D; Lentini M; Zappala D; Mannella A; Loiacono D; Gianfelici V; Panduri G; Gariani I; Minchella P; Talarico F; Levato L
Chemotherapy; 2022; 67(2):91-95. PubMed ID: 34872098
[TBL] [Abstract][Full Text] [Related]
30. Chilblain-Like Lesions (CLL) Coinciding With the SARS-CoV-2 Pandemic in Children: A Systematic Review.
Starkey SY; Kashetsky N; Lam JM; Dutz J; Mukovozov IM
J Cutan Med Surg; 2023; 27(3):277-284. PubMed ID: 37340564
[TBL] [Abstract][Full Text] [Related]
31. COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group.
Šimkovič M; Turcsányi P; Špaček M; Mihályová J; Ryznerová P; Maco M; Vodárek P; Écsiová D; Poul H; Móciková H; Zuchnická J; Panovská A; Lekaa M; Oršulová M; Prchlíková A; Stejskal L; Mašlejová S; Brychtová Y; Bezděková L; Papajík T; Lysák D; Trněný M; Smolej L; Doubek M
Ann Hematol; 2023 Apr; 102(4):811-817. PubMed ID: 36847805
[TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group.
Soboń A; Drozd-Sokołowska J; Paszkiewicz-Kozik E; Popławska L; Morawska M; Tryc-Szponder J; Bołkun Ł; Rybka J; Pruszczyk K; Juda A; Majeranowski A; Iskierka-Jażdżewska E; Steckiewicz P; Wdowiak K; Budziszewska B; Jamroziak K; Hus I; Lech-Marańda E; Puła B
Ann Hematol; 2023 Aug; 102(8):2119-2126. PubMed ID: 37392368
[TBL] [Abstract][Full Text] [Related]
33. Profiling post-COVID-19 condition across different variants of SARS-CoV-2: a prospective longitudinal study in unvaccinated wild-type, unvaccinated alpha-variant, and vaccinated delta-variant populations.
Canas LS; Molteni E; Deng J; Sudre CH; Murray B; Kerfoot E; Antonelli M; Rjoob K; Capdevila Pujol J; Polidori L; May A; Österdahl MF; Whiston R; Cheetham NJ; Bowyer V; Spector TD; Hammers A; Duncan EL; Ourselin S; Steves CJ; Modat M
Lancet Digit Health; 2023 Jul; 5(7):e421-e434. PubMed ID: 37202336
[TBL] [Abstract][Full Text] [Related]
34. Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge.
Bronstein Y; Levi S; Herishanu Y
Br J Haematol; 2023 Jun; 201(6):1125-1128. PubMed ID: 37042235
[TBL] [Abstract][Full Text] [Related]
35. Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes.
Guo W; Zheng Y; Feng S
Front Cell Infect Microbiol; 2023; 13():1207225. PubMed ID: 37928188
[TBL] [Abstract][Full Text] [Related]
36. Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic.
Langerbeins P; Eichhorst B
Acta Haematol; 2021; 144(5):508-518. PubMed ID: 33631756
[TBL] [Abstract][Full Text] [Related]
37. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
38. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.
Rogers KA; Lu X; Emond B; Côté-Sergent A; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
J Manag Care Spec Pharm; 2022 Sep; 28(9):1033-1045. PubMed ID: 35816124
[No Abstract] [Full Text] [Related]
39. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients.
Taquet M; Sillett R; Zhu L; Mendel J; Camplisson I; Dercon Q; Harrison PJ
Lancet Psychiatry; 2022 Oct; 9(10):815-827. PubMed ID: 35987197
[TBL] [Abstract][Full Text] [Related]
40. Management of patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic.
Mihaila RG
Oncol Lett; 2021 Aug; 22(2):636. PubMed ID: 34295383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
